United States Antimony
UAMY
3.72
-0.14
-3.63%
United States Antimony
US · UAMY
#3651 by market cap
3.72
-0.14
-3.63%
Live - 5344 symbols - heartbeat 446s ago
· 2026-10-08 10:11
Pre-market
3.80
-1.58%
After-hours
3.89
+0.78%
Overnight
3.85
-0.26%
- Market cap
- 556.77M
- P/E (TTM)i
- -28.62
- P/Bi
- 3.08
- EPSi
- -0.04
- Div yieldi
- 0.00%
- 52W posi
- 0%
Reader sentiment
Are you bullish or bearish on UAMY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 25.75, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +162.81% YoY
Margins
- Gross margin
- 25.15%
- Operating margin
- -22.61%
- Net margin
- -11.07%
Key ratios & quality
- Enterprise valuei
- 521.93M
- Altman Z-Scorei
- 25.75
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.03M | 8.27M | 5.24M | 7.75M | 11.04M | 8.69M | 14.94M | 39.26M |
| Gross profit | 1.54K | -816.25K | 205.70K | 838.61K | 2.00M | -3.34M | 3.47M | 9.87M |
| Selling & admin expenses | 1.54M | 1.44M | 1.22M | 1.24M | 1.44M | 2.92M | 5.37M | 17.06M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | -1.65M | -2.34M | -2.99M | -586.00K | 348.21K | -6.85M | -2.38M | -8.88M |
| Pretax profit | 540.89K | -3.67M | -3.29M | -60.47K | 444.73K | -6.35M | -1.73M | -4.34M |
| Tax | -332.33K | -- | -- | 0 | 16.07K | 0 | 0 | 0 |
| Net profit | 873.23K | -3.67M | -3.29M | -60.47K | 428.66K | -6.35M | -1.73M | -4.34M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.01 | -0.05 | -0.05 | 0.00 | 0.00 | -0.06 | -0.02 | -0.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 7.00M | 10.53M | 8.70M | 13.03M | 6.78M | 7.93M |
| Gross profit | 2.37M | 2.84M | 2.01M | 2.65M | 1.11M | 583.30K |
| Selling & admin expenses | 1.93M | 2.74M | 6.35M | 6.04M | 8.49M | 6.92M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 357.49K | 20.01K | -5.40M | -3.86M | -7.52M | -6.98M |
| Pretax profit | 546.52K | 181.56K | -4.78M | -286.91K | -11.28M | 166.80K |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 546.52K | 181.56K | -4.78M | -286.91K | -11.29M | 110.29K |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.00 | 0.00 | -0.04 | -0.01 | -0.08 | 0.00 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.90M | 1.28M | 1.81M | 23.57M | 21.62M | 14.08M | 20.68M | 54.74M |
| Cash & ST investments | 56.65K | 115.51K | 665.10K | 21.36M | 19.06M | 11.90M | 18.17M | 35.07M |
| Inventory | 755.26K | 626.24K | 650.21K | 1.06M | 1.38M | 1.39M | 1.25M | 12.52M |
| Total assets | 17.56M | 13.69M | 13.30M | 35.00M | 34.70M | 28.09M | 34.64M | 153.93M |
| Total current liabilities | 3.52M | 3.98M | 4.48M | 2.07M | 2.22M | 897.46K | 4.01M | 10.18M |
| Short-term debt | 889.38K | 253.40K | 152.12K | 13.23K | 94.15K | 28.44K | 758.81K | 171.05K |
| Long-term debt | 1.03M | 76.76K | 477.70K | 201.92K | 217.86K | -- | 195.43K | 58.48K |
| Total liabilities | 6,132,289.00 | 5,226,833.00 | 6,113,113.00 | 2,633,924.00 | 2,831,195.00 | 2,574,027.00 | 6,041,929.00 | 12,970,480.00 |
| Total equity | 11.42M | 8.47M | 7.19M | 32.37M | 31.87M | 25.52M | 28.60M | 140.96M |
| Retained earnings | -25.69M | -29.36M | -32.65M | -32.71M | -33.07M | -39.42M | -41.15M | -45.49M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 24.84M | 17.68M | 31.80M | 54.74M | 48.41M | 76.63M |
| Cash & ST investments | 18.75M | 6.97M | 19.61M | 35.07M | 7.84M | 46.10M |
| Inventory | 3.99M | 6.81M | 8.41M | 12.52M | 22.03M | 21.61M |
| Total assets | 39.50M | 47.50M | 79.88M | 153.93M | 148.05M | 190.62M |
| Total current liabilities | 4.72M | 8.00M | 6.26M | 10.18M | 13.37M | 6.64M |
| Short-term debt | 586.24K | 727.27K | 164.74K | 171.05K | 165.62K | 195.85K |
| Long-term debt | 161.64K | 127.55K | 93.17K | 58.48K | 23.50K | 158.86K |
| Total liabilities | 6,905,442.00 | 9,992,379.00 | 8,131,411.00 | 12,970,480.00 | 16,154,573.00 | 9,594,876.00 |
| Total equity | 32.59M | 37.51M | 71.75M | 140.96M | 131.89M | 181.02M |
| Retained earnings | -40.60M | -40.42M | -45.20M | -45.49M | -56.78M | -56.67M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -656.63K | -11.36K | -1.31M | -2.43M | -249.28K | -4.75M | 2.22M | -9.69M |
| Depreciation & amortization | 904.84K | 895.99K | 885.84K | 880.88K | 909.22K | 959.45K | 1.09M | 1.17M |
| Free cash flow | -1.56M | -804.28K | -1.55M | -3.08M | -1.98M | -6.28M | 1.79M | -37.50M |
| Dividends paid | -- | -- | -- | -- | 0 | -787.73K | -- | -- |
| Stock buybacks / issuance | 0 | 404.20K | 1.81M | 23.34M | -202.98K | 0 | 2.76M | 103.76M |
| Ending cash balance | 113.90K | 172.77K | 722.38K | 21.42M | 19.12M | 11.95M | 18.27M | 30.66M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -1.73M | -627.70K | -3.86M | -3.47M | -12.06M | -8.66M |
| Depreciation & amortization | 281.97K | 277.56K | 279.83K | 327.23K | 410.46K | 515.37K |
| Free cash flow | -2.59M | -7.16M | -12.54M | -15.21M | -24.64M | -18.89M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 2.39M | 2.67M | 32.97M | 65.73M | -3.64M | 44.93M |
| Ending cash balance | 18.85M | 5.81M | 18.47M | 30.66M | 3.38M | 42.25M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 7.58 | -37.52 | -42.76 | -0.55 | 1.19 | -22.16 | -6.42 | -5.13 |
| ROA %i | 4.75 | -23.82 | -24.71 | -0.45 | 1.09 | -20.24 | -5.54 | -4.61 |
| ROIC %i | 7.00 | -32.99 | -40.07 | -0.51 | 1.22 | -24.27 | -8.67 | -6.04 |
| 5-year avg ROE %i | -7.10 | -11.86 | -19.01 | -16.83 | -14.41 | -20.36 | -14.14 | -6.62 |
| EBIT margin %i | 7.09 | -43.48 | -62.44 | -0.71 | 4.16 | -78.81 | -15.93 | -22.61 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 11.98 | -- |
| Current ratioi | 0.54 | 0.32 | 0.40 | 11.38 | 9.74 | 15.68 | 5.16 | 5.38 |
| Quick ratioi | 0.25 | 0.10 | 0.20 | 10.75 | 8.94 | 13.96 | 4.82 | 4.11 |
| Debt / assetsi | 10.92 | 2.41 | 4.74 | 0.61 | 0.90 | 0.10 | 3.13 | 0.16 |
| LT debt / equityi | 9.02 | 0.91 | 6.67 | 0.62 | 0.68 | -- | 1.13 | 0.05 |
| Interest coveragei | 6.41 | -45.88 | -181.69 | -9.92 | 30.37 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -11.67 | -11.41 | -20.01 | -4.99 | 10.13 | 18.41 | 24.46 | 52.61 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -3.00 | -2.82 | -10.21 | -5.13 | -19.69 | -14.88 |
| ROA %i | -2.57 | -2.33 | -9.02 | -4.61 | -17.26 | -13.66 |
| ROIC %i | -5.31 | -4.89 | -11.45 | -6.04 | -20.68 | -15.92 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -8.32 | -6.24 | -19.13 | -22.61 | -42.91 | -65.18 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.26 | 2.21 | 5.08 | 5.38 | 3.62 | 11.54 |
| Quick ratioi | 4.39 | 1.19 | 3.43 | 4.11 | 1.92 | 7.94 |
| Debt / assetsi | 2.64 | 2.05 | 0.33 | 0.16 | 0.14 | 0.19 |
| LT debt / equityi | 1.40 | 0.65 | 0.14 | 0.05 | 0.03 | 0.09 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Antimony is the largest reported line at 76.52% of revenue, across 2 reported segments.
- The next-largest line, Zeolite, is a distant second at 23.48% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Antimony76.52%
Zeolite23.48%
Quote time 2026-10-08 10:11:22 · For reference only, not investment advice and not tailored to your situation.